Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Overview of attention for article published in Frontiers in immunology, November 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 7 X users

Readers on

mendeley: 98 Mendeley

Summary X

So far, Altmetric has seen 8 X posts from 7 X users, with an upper bound of 45,258 followers.

Excellent results of the 4th generación #CART in RR NHL with ORR 67% / CR 43% with 14% CRS (all grade 1) and 1 case of ICANS grade 3. IPI predictor of OS @FrontImmunol worth a read! https://t.co/NjII87qrVS

05 May 2021

Reply Repost Favourite

New Research: Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas: Background The administration of second- or third-generation anti-CD19 chimeric antigen… https://t.co/

03 Jan 2021

Reply Repost Favourite

RT @CARTTherapy: Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-H…

02 Jan 2021

Reply Repost Favourite

RT @CARTTherapy: Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-H…

19 Dec 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.